Literature DB >> 33473134

NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Donglin Ding1,2,3, Huixing Huang1,2, Quanfu Li1, Wenbo Yu2, Chenji Wang2, Haijie Ma4, Jiaxue Wu2, Yongjun Dang1, Long Yu5, Wei Jiang6.   

Abstract

Nuclear factor 90 (NF90), an RNA-binding protein, has been implicated in regulating interleukin-2 (IL-2) and the immune response. It was recently reported that NF90 is upregulated in hepatocellular carcinoma (HCC) tissues and promotes HCC proliferation through upregulating cyclin E1 at the posttranscription level. However, the regulation of NF90 in HCC remains unclear. We demonstrate here that cyclin-dependent kinase (CDK) 2 interacts with NF90 and phosphorylated it at serine382. Mechanistically, phosphorylation of NF90-Ser382 determines the nuclear export of NF90 and stabilization of cyclin E1 mRNA. We also demonstrate that the phosphorylation deficient mutant NF90-S382A inhibits cell growth and induces cell cycle arrest at the G1 phase in HCC cells. Moreover, an NF90-S382A xenograft tumor had a decreased size and weight compared with the wildtype NF90. The NF90-S382A xenograft contained a significantly lower level of the proliferation marker Ki-67. Additionally, in HCC patients, NF90-Ser382 phosphorylation was stronger in tumor than in non-tumor tissues. Clinically, phosphorylation of NF90-Ser382 is significantly associated with larger tumor sizes, higher AFP levels, and shorter overall survival rates. These results suggest NF90-Ser382 phosphorylation serves as a potential diagnosis and prognostic marker and a promising pharmacological target for HCC.

Year:  2020        PMID: 33473134     DOI: 10.1038/s41420-020-0236-9

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN: 2058-7716


  51 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 2.  Hepatocellular carcinoma: the need for progress.

Authors:  Melanie B Thomas; Andrew X Zhu
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

3.  Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90.

Authors:  P N Kao; L Chen; G Brock; J Ng; J Kenny; A J Smith; B Corthésy
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

Review 4.  Opportunities for targeted therapies in hepatocellular carcinoma.

Authors:  Melanie B Thomas; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 6.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

Authors:  Jessica Zucman-Rossi; Augusto Villanueva; Jean-Charles Nault; Josep M Llovet
Journal:  Gastroenterology       Date:  2015-06-20       Impact factor: 22.682

7.  Purification by DNA affinity chromatography of two polypeptides that contact the NF-AT DNA binding site in the interleukin 2 promoter.

Authors:  B Corthésy; P N Kao
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

8.  Nuclear export of NF90 is required for interleukin-2 mRNA stabilization.

Authors:  Jaekyung Shim; Hanjo Lim; John R Yates; Michael Karin
Journal:  Mol Cell       Date:  2002-12       Impact factor: 17.970

9.  NF90 selectively represses the translation of target mRNAs bearing an AU-rich signature motif.

Authors:  Yuki Kuwano; Rudolf Pullmann; Bernard S Marasa; Kotb Abdelmohsen; Eun Kyung Lee; Xiaoling Yang; Jennifer L Martindale; Ming Zhan; Myriam Gorospe
Journal:  Nucleic Acids Res       Date:  2009-10-22       Impact factor: 16.971

10.  NF90 regulates inducible IL-2 gene expression in T cells.

Authors:  Lingfang Shi; Wayne R Godfrey; Joseph Lin; Guohua Zhao; Peter N Kao
Journal:  J Exp Med       Date:  2007-04-30       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.